A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years

Trial Profile

A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2015

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Erosive oesophagitis; Gastro-oesophageal reflux
  • Focus Adverse reactions
  • Sponsors Takeda; Takeda Global Research and Development Center
  • Most Recent Events

    • 20 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 31 May 2013 Planned end sate changed from 1 Aug 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 06 Oct 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2012-001681-15).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top